Puma Biotechnology (PBYI) Stock Price, Quote & News

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 424 248 6500

Website: www.pumabiotechnology.com

Address:

10880 Wilshire Boulevard, Suite 2150, Los Angeles, United States

Jonnyking Jun. 11 at 8:17 PM

$PBYI if no data release before next er and no action from Alan (share buyback or buy share with his own money), we are going back to 3 or less before we reach back to 4+....they can take it back to 3 with less than 100k shares. Buy under 2.79. The fundamental value of PBYI is 10+, which has not been changed....

2 · Reply

PMD777 Jun. 10 at 2:54 PM

$PBYI WTH dumb stock

0 · Reply

Unicorn2020 Jun. 9 at 12:35 PM

$PBYI $4.10 today or tomorrow?

1 · Reply

Doozio Jun. 7 at 8:33 PM

$PBYI 🐒🍌🧠⏰♾️

0 · Reply

AmandaBlakes1061 Jun. 6 at 3:10 PM

$PBYI had its moment and now ZBAO is stepping into the spotlight with real movement.

0 · Reply

Jonnyking Jun. 5 at 8:00 PM

$PBYI Alan, please purchase 6m shares at this price and share buy back another 15m share with cash on hand (60m), you have about 50% of the company. Release the strong data for both small cell cancer, the market need new lung cancer drug....combining with the cure for pancreatic cancer, we are going to sky.... from 3.69 to 369 in one night....let's do it

0 · Reply

Awesom69Trade Jun. 5 at 3:43 PM

$PBYI Something big is brewing??

1 · Reply

Unicorn2020 Jun. 4 at 5:42 PM

$PBYI Small cell lung cancer drug ALISCA is in phase II now. The result should be coming out any time this summer. A successfully transition from Phase 2 to Phase 3 clinical trials will send us to $8 level. A better result higher than 70% will make BO happen with $24/share instantly. Cross our fingers.

2 · Reply

Tommystar2121 Jun. 4 at 5:14 PM

$OSCR $PBYI

0 · Reply

PharmaExpert Jun. 4 at 4:29 PM

$AKBA, $AGEN, $IBIO, $INMB, $PBYI 🔥🔥🔥🔥🔥

0 · Reply

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 9:08 AM EDT - 5 weeks ago

Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 5 weeks ago

Puma Biotechnology Reports First Quarter Financial Results

Apr 30, 2025, 6:00 AM EDT - 6 weeks ago

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Apr 28, 2025, 3:03 PM EDT - 7 weeks ago

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Apr 24, 2025, 4:11 PM EDT - 7 weeks ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Mar 31, 2025, 4:53 AM EDT - 2 months ago

Puma SE: Undervalued With Tailwinds Ahead

Mar 26, 2025, 9:00 AM EDT - 2 months ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 21, 2025, 7:46 AM EDT - 3 months ago

PUMA SE: This Is The Right Time To Buy

Mar 5, 2025, 5:30 PM EST - 3 months ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Feb 27, 2025, 9:02 PM EST - 3 months ago

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 3 months ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:15 PM EST - 3 months ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:15 PM EST - 4 months ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 9:01 AM EST - 6 months ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 16, 2024, 11:36 AM EST - 6 months ago

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Nov 20, 2024, 8:57 AM EST - 7 months ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 7, 2024, 11:09 PM EST - 7 months ago

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:05 PM EST - 7 months ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 4:07 PM EDT - 8 months ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Sep 3, 2024, 4:15 PM EDT - 10 months ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 10:54 PM EDT - 11 months ago

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 11 months ago

Puma Biotechnology Reports Second Quarter Financial Results

Jul 18, 2024, 4:10 PM EDT - 11 months ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jun 3, 2024, 2:33 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 2, 2024, 10:01 AM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

May 28, 2024, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Join Russell 3000 Index

May 23, 2024, 5:15 PM EDT - 1 year ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 2, 2024, 10:11 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Feb 29, 2024, 8:39 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 15, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Jan 11, 2024, 4:07 PM EST - 1 year ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Dec 14, 2023, 1:41 AM EST - 1 year ago

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Dec 11, 2023, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Nov 2, 2023, 10:21 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:14 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Sep 21, 2023, 4:10 PM EDT - 1 year ago

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Aug 31, 2023, 4:07 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

Aug 3, 2023, 10:57 PM EDT - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript

Jul 20, 2023, 4:15 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

Jun 4, 2023, 9:00 AM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Jonnyking Jun. 11 at 8:17 PM

2 · Reply

PMD777 Jun. 10 at 2:54 PM

$PBYI WTH dumb stock

0 · Reply

Unicorn2020 Jun. 9 at 12:35 PM

$PBYI $4.10 today or tomorrow?

1 · Reply

Doozio Jun. 7 at 8:33 PM

$PBYI 🐒🍌🧠⏰♾️

0 · Reply

AmandaBlakes1061 Jun. 6 at 3:10 PM

$PBYI had its moment and now ZBAO is stepping into the spotlight with real movement.

0 · Reply

Jonnyking Jun. 5 at 8:00 PM

0 · Reply

Awesom69Trade Jun. 5 at 3:43 PM

$PBYI Something big is brewing??

1 · Reply

Unicorn2020 Jun. 4 at 5:42 PM

2 · Reply

Tommystar2121 Jun. 4 at 5:14 PM

$OSCR $PBYI

0 · Reply

PharmaExpert Jun. 4 at 4:29 PM

$AKBA, $AGEN, $IBIO, $INMB, $PBYI 🔥🔥🔥🔥🔥

0 · Reply

Awesom69Trade Jun. 4 at 3:57 PM

$PBYI Buyout for $15.69 a share so I can buy a new car please!!

0 · Reply

Richkid Jun. 4 at 3:45 PM

$PBYI what’s happening.. This run is unusual

1 · Reply

Unicorn2020 Jun. 4 at 3:41 PM

$PBYI Give me a $12/share BO, my 50K shares @ $3.00 average will net me $600,000K profit. All my own money was all out @ $5 the year before.

1 · Reply

Jonnyking Jun. 4 at 3:30 PM

$PBYI it is about time, long term debt is almost paid off, 90m cash and cash equivalent, 210m - 220m net revenue till 2030 pipelines of combo with AZN could provide a cure for pancreatic cancer. Trading under 200m makes no sense... minimally, 500m to 600m. With strong pipeline data, 1b+ to 2b

0 · Reply

Awesom69Trade Jun. 4 at 3:09 PM

$PBYI Why so high volume back to back day? Someone knows something?

1 · Reply

PSDL75 Jun. 4 at 2:33 PM

$PBYI we break $3.60 today we get all the BO posts and eyeballs

0 · Reply

PSDL75 Jun. 4 at 2:22 PM

$PBYI perhaps whoever kept this down has covered based on this movement

1 · Reply

PSDL75 Jun. 3 at 6:13 PM

$PBYI Long drop but shows up green tells they took out some stop losses

2 · Reply

Jonnyking Jun. 3 at 6:00 PM

$PBYI someone just bought 1 m shares? is this a buyback from Alan? what would be awesome...

1 · Reply

Cinderella74 Jun. 2 at 1:52 PM

$PBYI nothing new just the usual.

0 · Reply

Jonnyking May. 27 at 12:38 AM

$PBYI https://clinicaltrials.gov/study/NCT05372614?term=neratinib%20NOT%20Puma%20AND%20NOT%20ASLAN001&viewType=Table&rank=22 this should be completed by June 1st. If a phase 2 study is approved, I do believe we have a chance to be bought by AZN

2 · Reply

yurched May. 23 at 11:43 AM

$PBYI Found a hidden gem and joined this stock. Wish I had heard about this company earlier.

2 · Reply

Market Cap	166.26M
Revenue (ttm)	230.47M
Net Income (ttm)	30.28M
EPS (ttm)	N/A
PE Ratio	4.62
Forward PE	6.98
Profit Margin	13.14%
Debt to Equity Ratio	0.58

Volume	228,779
Avg Vol	363,722
Day's Range	N/A - N/A
Shares Out	49.63M
Stochastic %K	30%
Beta	1.29
Analysts	Hold
Price Target	$4.33